⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8352097 | 0.81 | PTGS1 (0.55) | — | |
| SCHEMBL6930529 | 0.79 | — | — | |
| SCHEMBL15514169 | 0.79 | — | — | |
| SCHEMBL19934871 | 0.79 | — | — | |
| SCHEMBL16317759 | 0.79 | — | — | |
| SCHEMBL4297372 | 0.77 | — | — | |
| SCHEMBL12519877 | 0.77 | — | — | |
| SCHEMBL929197 | 0.77 | — | — | |
| SCHEMBL12852243 | 0.77 | — | — | |
| SCHEMBL27787146 | 0.77 | PTGS1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1005361-B1 | USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ENDOTHELIAL DYSFUNKTION AND FOR THE INHIBITION OF ANGIOGENESIS RESPECTIVELY | NOVO NORDISK HEALTHCARE AG (CH) | 2010-01-06 | — | — | EP | claimed |
| EP-1005361-A1 | USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ADVERSE CONDITIONS RELATED TO THE FVIIa MEDIATED INTRACELLULAR SIGNALLING PATHWAY | NOVO NORDISK A/S (DK) | 2000-06-07 | — | — | EP | claimed |
| WO-1999003498-A1 | USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ADVERSE CONDITIONS RELATED TO THE FVIIa MEDIATED INTRACELLULAR SIGNALLING PATHWAY | NOVO NORDISK A/S (DK) | 1999-01-28 | — | — | WO | claimed |
| WO-1997049684-A1 | FACTOR VII-BINDING REAGENT | NOVO NORDISK A/S (DK) | 1997-12-31 | — | — | WO | claimed |
| CN-120005067-A | Gel cation exchange resin and preparation method and application thereof | 江苏金杉新材料有限公司 | 2025-05-16 | — | — | CN | disclosed |
| EP-1005361-B1 | USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ENDOTHELIAL DYSFUNKTION AND FOR THE INHIBITION OF ANGIOGENESIS RESPECTIVELY | NOVO NORDISK HEALTHCARE AG (CH) | 2010-01-06 | — | — | EP | disclosed |
| US-20070232542-A1 | Methods for Modifying Cell Motility Using Factor VIIa Antagonist | NOVO NORDISK A/S (DK) | 2007-10-04 | — | — | US | disclosed |
| US-20050245449-A1 | Methods for modifying cell motility using factor VIIa antagonist | NOVO NORDISK, A/S (DK) | 2005-11-03 | — | — | US | disclosed |
| US-20030040481-A1 | Methods for modifying cell motility using a factor VIIa antagonist | NOVO NORDISK HEALTHCARE A/G (CH) | 2003-02-27 | — | — | US | disclosed |
| US-6461610-B1 | Methods for modifying cell motility using factor VIIa or inactivated factor VIIa | NOVO NORDISK A/S (DK) | 2002-10-08 | — | — | US | disclosed |
| US-6268163-B1 | DETECTION OF MODULATORS OF MEMBRANE PROTEIN ACTIVITY; CULTURE CELLS, MEASURE ACTIVATION OF MITOGEN ACTIVATED PROTEIN KINASE, COMPARE WITH CONTROL, ADJUSTMENT IN ACTIVATION INDICATES MODULATION OF SIGNAL TRANSDUCTION | NOVO NORDISK A/S (DK) | 2001-07-31 | — | — | US | disclosed |
| EP-1005361-A1 | USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ADVERSE CONDITIONS RELATED TO THE FVIIa MEDIATED INTRACELLULAR SIGNALLING PATHWAY | NOVO NORDISK A/S (DK) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999003498-A1 | USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ADVERSE CONDITIONS RELATED TO THE FVIIa MEDIATED INTRACELLULAR SIGNALLING PATHWAY | NOVO NORDISK A/S (DK) | 1999-01-28 | — | — | WO | disclosed |
| US-5859010-A | ANTICOAGULANTS | NOVO NORDISK A/S (DK) | 1999-01-12 | — | — | US | disclosed |
| WO-1997049684-A1 | FACTOR VII-BINDING REAGENT | NOVO NORDISK A/S (DK) | 1997-12-31 | — | — | WO | disclosed |